Core Biogenesis’ Post

The plant-based recombinant protein revolution is here! Get your thermostabilized FGF-2 today and incorporate sustainability and ultra-scalability into your processes.

The isolation of ultra-rare cell populations is no longer a challenge with the latest advancements in cell therapy manufacturing. The CGX10 Cell Isolation System by Sony is designed to deliver high-purity sorting of even the most elusive cells, such as Foxp3-positive naïve regulatory T cells (nTregs), which make up less than 1% of a leukocyte sample. Join Sony Biotechnology Inc. exclusive webinar to dive deep into the CGX10 system’s capabilities, including: 📊 High-efficiency sorting: Achieve >97% purity of transduced T cells expressing GFP 🔬 Advanced workflows: Direct isolation of Foxp3-positive nTregs from a single donor leukopak 🔧 Customizable purity modes: Optimized sorting of CD4+ and CD8+ T cells after RBC lysis Learn how these clinical-grade cell sorting processes can streamline your therapeutic development and manufacturing pipeline. Thursday, October 10, 2024, at 09:00 PDT / 12:00 EDT / 16:00 BST Don't miss out on this chance to enhance your research capabilities. 👉 Register now: https://lnkd.in/eytTrkbw #CellTherapy #GeneTherapy #UltraRareCells #CGX10System #ScientificInnovation #Biotech

SRI is collaborating with N4 Pharma Plc to target intracellular delivery of cargo that has historically been undruggable. SRI’s FOX Three Molecular Guidance System (MGS)™ platform technology will be conjugated to N4’s novel drug delivery system, called Nuvec ™, which focuses on delivery of nucleic acid cargo. Combining these technologies will enable targeted, intracellular delivery of bio-therapeutics to specific cells and help realize the full potential of precision medicine. “This strategic partnership marks an exciting journey toward expanding treatment possibilities and transforming the landscape of biomedicine,” says SRI Biosciences’ president, Kathlynn Brown. Read the story: https://lnkd.in/eppnR7de #precisionmedicine #drugdelivery

𝐂𝐞𝐥𝐥 𝐈𝐬𝐨𝐥𝐚𝐭𝐢𝐨𝐧 & 𝐒𝐞𝐩𝐚𝐫𝐚𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐨𝐢𝐬𝐞𝐝 𝐟𝐨𝐫 𝐑𝐞𝐦𝐚𝐫𝐤𝐚𝐛𝐥𝐞 𝐆𝐫𝐨𝐰𝐭𝐡! 🔬 Download PDF Brochure: https://lnkd.in/dDfQ5SsV The global Cell Isolation/Separation Market is set to experience a transformative journey, projected to surge from USD 4.6 billion in 2024 to an impressive USD 8.4 billion by 2029. That's a compelling Compound Annual Growth Rate (CAGR) of 12.9%! 📈 Key Drivers Powering This Growth: • Accelerating R&D investments in cell-based research • Cutting-edge technological advancements • Expanding applications across biomolecule and cancer research Market Snapshot: ✅ Product Diversity: Consumables (Media, Kits), Instruments ✅ Cell Sources: Human and Animal Cells ✅ Techniques: Centrifugation, Filtration ✅ Key Application Areas: Biomolecule Research, Cancer Studies Challenges Ahead: ⚠️ High costs of cell-based research may pose potential market constraints 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Merck Group, Danaher Corporation, Thermo Fisher Scientific, BD, Agilent Technologies, Miltenyi Biotec, Revvity, Sartorius, F. Hoffmann-La Roche Ltd. (Switzerland), Lonza, QIAGEN, Alfa Laval, Terumo Medical Corporation, Corning Incorporated, Bio-Rad Laboratories, GenScript, Bio-Techne, Takara Bio Inc., Standard BioTools, Promega Corporation , Cell Signaling Technology (CST), and STEMCELL Technologies Other Companies that are Operating in this Market Globally: Royan Stem Cell Technology Co. ALPHA BIO CELL Zhongyuan Union Stem Cell Bioengineering Co  Hamilton Company Tune Therapeutics Telesis Bio Brooks Life Sciences C4 Therapeutics, Inc. MaxCyte, Inc. Eurofins Discovery 2seventy bio Nucleus Biologics HiFiBiO Therapeutics Allogene Therapeutics Pillar Biosciences Incorporated Novogene America ATUM Century Therapeutics, Inc NKGen Biotech, Inc. #CellResearch #Biotechnology #LifeSciences #MarketTrends #Innovation

🔬🧬 Dive into the world of biopharmaceutical characterization! 💉✨ Understanding the intact mass and structural heterogeneity of recombinant antibodies is crucial in our industry. Intact mass analysis using mass spectrometry is a cornerstone technique from process development to product analysis. ⚙️ But with processes in place, we need efficient methods to characterize products and their variants. Enter microfluidic capillary electrophoresis mass spectrometry (μCE-MS) – a high-throughput solution providing timely feedback for optimization. 🔍 The μCE-MS platform integrates capillary electrophoresis with electrospray ionization-based mass spectrometry on a microfluidic chip. This ZipChip system offers portability and compatibility with various biomatrices, ensuring accurate and rapid data for biopharmaceutical drug development. 🌟 Stay ahead in biopharma with cutting-edge characterization techniques! ➡️https://ow.ly/SlJc50RbkvG #Biopharmaceuticals #Characterization #MassSpectrometry #Innovation #Neuroscience #WASMagazine

I am thrilled to share that our #review paper, "The Opportunities and Challenges of Mesenchymal Stem Cells-Derived Exosomes in Theranostics and Regenerative Medicine", has been published in Cells MDPI (Impact Factor: 5.1)! 🎉 I want to thank everyone who supported and contributed to this review, especially my Guide, Dr. Kausik Kapat, 📖 Read the full article here: https://lnkd.in/dDpdFtPw 🚀#Research #Publication #RegenerativeMedicine #Theranostics #Exosomes #StemCells #NIPERKolkata #CellsMDPI #niper #cells #pharmaceuticals

Regenerative Medicine Market to Grow $49.0 Billion by 2028 Download Sample PDF Report-https://lnkd.in/d-nBeBC8 The global regenerative medicine market's revenue was estimated to be worth $16.0 Billion in 2023 and is poised to reach $49.0 Billion by 2028, growing at a CAGR of 25.1% from 2023 to 2028. Companies Working in the Market Aziyo Biologics, Inc.     BioCardia, Inc. Direct Biologics Pinnacle Transplant Technologies      Reliance Life Sciences Pvt. Ltd. STEMCELL Technologies Thrive Bioscience, Inc.    ProKidney Corp. Laurus Bio Gel4Med, Inc. CCRM AgNovos Bioscience BTI Biotechnology Institute      Kerecis Deep Knowledge Group     Collagen Solutions      Comecer BioLab Sciences    Pluri Geistlich Pharma INDIBA Group Celltex Therapeutics Corporation  RegenLab USA      BRINTER Stem Cell Network      REGROW BIOSCIENCES TEI Biosciences Inc HUB Organoids    Pandorum Technologies      CollPlant Longeveron Inc  Rion MERLN Institute for Technology-Inspired Regenerative Medicine      REGEMAT 3D APEX Biologix HTL Biotechnology Cell Therapies Pty Ltd Wyss Zurich Mogrify International Stem Cell Corporation 

Excited for Sony Biotechnology Inc. x Phacilitate webinar today - sign up for free below! Join our webinar to find out about isolating ultra- rare cell populations at high purity using the CGX10 Cell Isolation System with Sony. The isolation and expansion of rare and ultra-rare cell populations are important for advancing cell therapy manufacturing. For example, Foxp3-positive naïve regulatory T cells (nTregs) may account for <1% of cells in a sample containing 1 billion leukocytes, making it extremely challenging to isolate them with high purity. In this webinar, Sony Biotechnology Inc. will provide data on how the CGX10 Cell Isolation System can sort these ultra-rare nTregs directly from a leukopak. We also will share data on how the CGX10 system can be utilized for isolation of positively transduced T cells expressing a green fluorescent protein (GFP) marker at >97% purity using Purity mode. This webinar will describe how the CGX10 Cell Isolation System can be used to perform the following clinical-grade cell sorting workflow processes: • High throughput sterile isolation and expansion of Foxp3-positive nTregs from 1 billion human leukocytes from a single donor, bypassing any bead-based pre-enrichment steps • Isolation of positively transduced T cells expressing a GFP marker at high purity • Sorting of CD4+ and CD8+ T cells directly after an RBC lysis step, at a predefined proportion, using Custom Purity mode Don’t miss out—register now for this exclusive webinar. #biotechnology #celltherapy #genetherapy #cellandgenetherapy #biotech #isolationsystem #SONYBiotechnology #Phacilitate #RegulatoryTCells #Biomanufacturing

𝐂𝐞𝐥𝐥 𝐂𝐮𝐥𝐭𝐮𝐫𝐞 𝐌𝐞𝐝𝐢𝐚 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐯𝐞𝐧𝐮𝐞 𝐄𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐭𝐨 𝐑𝐞𝐚𝐜𝐡 $𝟏𝟑.𝟎 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟐𝟖 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐚𝐭 https://lnkd.in/dNMpEu8m The global cell culture media market in terms of revenue was estimated to be worth $6.2 billion in 2023 and is poised to reach $13.0 billion by 2028, growing at a CAGR of 16.0% from 2023 to 2028. Recent Developments of Cell Culture Media Industry: - In June 2023, Thermo fisher launched Tumoroid Culture Medium to accelerate development of novel cancer therapies. - In April 2023, FUJIFILM Irvine Scientific launched BalanCD CHO Media Platform Portfolio for Bioprocessing. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: Thermo Fisher Scientific Merck Life Science Danaher Corporation Sartorius Corning Incorporated FUJIFILM Holdings Corporation Lonza Becton, Dickinson and Company STEMCELL Technologies STEMCELL Technologies China Miltenyi Biotec HiMedia Laboratories Pvt. Ltd. BIOLOGOS Cell Applications, Inc. Caisson Laboratories PromoCell Cell Biologics, Inc InvivoGen PAN-Biotech GmbH Cellular Technology Limited — CTL ZenBio Athena Enzyme Systems Cyagen BIOSCIENCES Cyagen Korea Biowest Akron BioTECH KCell Biosciences Welgene Inc. faCellitate Biological Industries Sartorius Nucleus Biologics Bitesize Bio Superworth Biodiscoveries Pvt. Ltd. SIGNICENT PELOBiotech GmbH ATCC #cellculturemedia #cellculturemediamarket #cellculturemediamarketsize #cellculturemediacompanies #biotech #biotechnology

🚀 Nanoclick: Pioneering receptor-mediated internalization Back to groundbreaking research on "Receptor-Mediated Internalization" presented by Viviana Gatta from UCB Biopharma at the Promega Innovation Days in Leuven. 🔬 Abstract: Cytosolic bioavailability limits the development of intracellular therapeutics. In contrast to small molecules, permeability of peptides across the plasma membrane is rarely achieved, and receptor-mediated internalization often leads to their degradation in the lysosomes. Nanoclick, a high-throughput and target-agnostic assay, combines click chemistry and Nano-Bret signal to directly quantify the amount of peptides or small molecules effectively reaching the cytosol. This method allows to optimize molecules based on their structure, activity and permeability, offering a flexible setup for various therapeutics and targets. 👏 Congratulations to Viviana Gatta and her team for this innovative work: Martine Geraerts (UCB), Noémie Willain (Novalix), Davide Proverbio (Novalix). 🤝 Insourcing, a unique collaborative model: Novalix partners with UCB Biopharma to provide discovery services on client’s site. This model fosters close collaboration, faster turnaround, and improved cost efficiency. ▶ Check out the full abstract and learn more about our innovative approaches in drug discovery: https://lnkd.in/e9pv2Rns #DrugDiscovery #Innovation #Nanoclick #Teamwork #Insourcing #Biopharma UCB